Astra Zeneca

AstraZeneca-Oxford Covid Vaccine May Be Adapted for New Variants

Researchers are planning to develop a new version of the Oxford-AstraZeneca vaccine tailored to protect against new variants of SARS-CoV-2.

The original vaccine was found to be less effective against the South African variant of the coronavirus in a clinical trial in South Africa.

A team of scientists at the University of Oxford are working on a new version of the Oxford-AstraZeneca vaccine that will be more effective against new variants of SARS-CoV-2, the virus that causes COVID-19.

The original Oxford-AstraZeneca vaccine was found to be less effective against the South African variant of the coronavirus in a clinical trial in South Africa, although it is still effective against the original strain of the virus and the UK variant.

The new vaccine will be based on the same platform as the original vaccine, but it will be modified to include a protein that is specific to the South African variant of the virus. This will allow the vaccine to generate antibodies that are more effective at neutralizing the South African variant.

The researchers are also planning to develop a version of the vaccine that will protect against multiple variants of the virus. This will be done by including a combination of proteins from different variants in the vaccine.

The new vaccine is expected to be ready for clinical trials in the coming months. If the trials are successful, the vaccine could be available to the public by the end of the year.